76 results on '"Lisa M. Monteggia"'
Search Results
2. Optical analysis of AMPAR-mediated synaptic scaling in mouse hippocampus
- Author
-
Kanzo Suzuki, Ege T. Kavalali, and Lisa M. Monteggia
- Subjects
Cell Biology ,Microscopy ,Neuroscience ,Science (General) ,Q1-390 - Abstract
Summary: Immunolabeling of surface AMPA receptors (AMPARs) can be used for in vivo or ex vivo examination of synaptic scaling, a type of homeostatic plasticity. Here, we present a protocol to analyze changes in synaptic weights using immunohistochemistry for surface AMPARs coupled with optical imaging analysis. We detail immunostaining of AMPARs in mouse brain sections, followed by confocal imaging of surface AMPARs in dendritic region of hippocampal CA1. We then describe using Fiji/ImageJ and rank order plots for analyzing synaptic weight.For complete details on the use and execution of this protocol, please refer to Suzuki et al. (2021). : Publisher’s note: Undertaking any experimental protocol requires adherence to local institutional guidelines for laboratory safety and ethics.
- Published
- 2022
- Full Text
- View/download PDF
3. Sustained effects of rapidly-acting antidepressants require BDNF-dependent MeCP2 phosphorylation
- Author
-
Megumi Adachi, Anita E. Autry, Ji Woon Kim, Elisa S. Na, Carl Björkholm, Ege T. Kavalali, and Lisa M. Monteggia
- Subjects
0301 basic medicine ,Methyl-CpG-Binding Protein 2 ,Scopolamine ,Article ,MECP2 ,Mice ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Animals ,Ketamine ,Phosphorylation ,Mice, Knockout ,Neuronal Plasticity ,business.industry ,Extramural ,Brain-Derived Neurotrophic Factor ,General Neuroscience ,Brain ,Antidepressive Agents ,Mice, Inbred C57BL ,030104 developmental biology ,Synaptic plasticity ,Antidepressant ,business ,Neuroscience ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The rapidly acting antidepressants ketamine and scopolamine exert behavioral effects that can last from several days to more than a week in some patients. The molecular mechanisms underlying the maintenance of these antidepressant effects are unknown. Here we show that methyl-CpG-binding protein 2 (MeCP2) phosphorylation at Ser421 (pMeCP2) is essential for the sustained, but not the rapid, antidepressant effects of ketamine and scopolamine in mice. Our results reveal that pMeCP2 is downstream of BDNF, a critical factor in ketamine and scopolamine antidepressant action. In addition, we show that pMeCP2 is required for the long-term regulation of synaptic strength after ketamine or scopolamine administration. These results demonstrate that pMeCP2 and associated synaptic plasticity are essential determinants of sustained antidepressant effects.
- Published
- 2021
4. A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action
- Author
-
Ege T. Kavalali, Ji Woon Kim, Lisa M. Monteggia, and Joachim Herz
- Subjects
Male ,Low-density lipoprotein receptor-related protein 8 ,Neurotransmission ,Receptors, N-Methyl-D-Aspartate ,Mice ,Phosphatidylinositol 3-Kinases ,Postsynaptic potential ,Animals ,Reelin ,LDL-Receptor Related Proteins ,Multidisciplinary ,Neuronal Plasticity ,biology ,Behavior, Animal ,Biological Sciences ,DAB1 ,Antidepressive Agents ,Reelin Protein ,src-Family Kinases ,nervous system ,Synaptic plasticity ,biology.protein ,NMDA receptor ,Ketamine ,Synaptic signaling ,Neuroscience ,Signal Transduction - Abstract
Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that produces rapid antidepressant action in some patients with treatment-resistant depression. However, recent data suggest that ∼50% of patients with treatment-resistant depression do not respond to ketamine. The factors that contribute to the nonresponsiveness to ketamine's antidepressant action remain unclear. Recent studies have reported a role for secreted glycoprotein Reelin in regulating pre- and postsynaptic function, which suggests that Reelin may be involved in ketamine's antidepressant action, although the premise has not been tested. Here, we investigated whether the disruption of Reelin-mediated synaptic signaling alters ketamine-triggered synaptic plasticity and behavioral effects. To this end, we used mouse models with genetic deletion of Reelin or apolipoprotein E receptor 2 (Apoer2), as well as pharmacological inhibition of their downstream effectors, Src family kinases (SFKs) or phosphoinositide 3-kinase. We found that disruption of Reelin, Apoer2, or SFKs blocks ketamine-driven behavioral changes and synaptic plasticity in the hippocampal CA1 region. Although ketamine administration did not affect tyrosine phosphorylation of DAB1, an adaptor protein linked to downstream signaling of Reelin, disruption of Apoer2 or SFKs impaired baseline NMDA receptor-mediated neurotransmission. These results suggest that maintenance of baseline NMDA receptor function by Reelin signaling may be a key permissive factor required for ketamine's antidepressant effects. Taken together, our results suggest that impairments in Reelin-Apoer2-SFK pathway components may in part underlie nonresponsiveness to ketamine's antidepressant action.
- Published
- 2021
5. Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action
- Author
-
Eero Castrén and Lisa M. Monteggia
- Subjects
0301 basic medicine ,Tropomyosin receptor kinase B ,Receptor tyrosine kinase ,03 medical and health sciences ,0302 clinical medicine ,Neurotrophic factors ,Neuroplasticity ,Medicine ,Humans ,Receptor, trkB ,Biological Psychiatry ,Brain-derived neurotrophic factor ,biology ,business.industry ,Depression ,Mood Disorders ,Brain-Derived Neurotrophic Factor ,medicine.disease ,Antidepressive Agents ,030104 developmental biology ,nervous system ,Mood disorders ,biology.protein ,Antidepressant ,business ,Neuroscience ,030217 neurology & neurosurgery ,Neurotrophin ,Signal Transduction - Abstract
Neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor), have been associated with depression and antidepressant drug action. A variety of preclinical and clinical studies have implicated impaired BDNF signaling through its receptor TrkB (neurotrophic receptor tyrosine kinase 2) in the pathophysiology of mood disorders, but many of the initial findings have not been fully supported by more recent meta-analyses, and more both basic and clinical research is needed. In contrast, increased expression and signaling of BDNF has been repeatedly implicated in the mechanisms of both typical and rapid-acting antidepressant drugs, and recent findings have started to elucidate the mechanisms through which antidepressants regulate BDNF signaling. BDNF is a critical regulator of various types of neuronal plasticities in the brain, and plasticity has increasingly been connected with antidepressant action. Although some equivocal data exist, the hypothesis of a connection between neurotrophic factors and neuronal plasticity with mood disorders and antidepressant action has recently been further strengthened by converging evidence from a variety of more recent data reviewed here.
- Published
- 2021
6. Role of Aberrant Spontaneous Neurotransmission in SNAP25-Associated Encephalopathies
- Author
-
Lisa M. Monteggia, Rong Sun, Ok-Ho Shin, Pei-Yi Lin, K Ian White, Baris Alten, Qiangjun Zhou, Axel T. Brunger, Ege T. Kavalali, Luis Esquivies, and Wendy K. Chung
- Subjects
0301 basic medicine ,Male ,Adolescent ,Synaptosomal-Associated Protein 25 ,Synaptobrevin ,Mice, Transgenic ,Haploinsufficiency ,Neurotransmission ,Biology ,Synaptic Transmission ,Synaptotagmin 1 ,Protein Structure, Secondary ,Rats, Sprague-Dawley ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Syntaxin ,Animals ,Humans ,Amino Acid Sequence ,Neurotransmitter ,Receptor ,Child ,Cells, Cultured ,Mice, Knockout ,Brain Diseases ,General Neuroscience ,SNAP25 ,Phenotype ,Rats ,030104 developmental biology ,HEK293 Cells ,chemistry ,Child, Preschool ,Female ,Neuroscience ,030217 neurology & neurosurgery - Abstract
SNARE (soluble N-ethylmaleimide sensitive factor attachment protein receptor) complex, composed of synaptobrevin, syntaxin, and SNAP25, forms the essential fusion machinery for neurotransmitter release. Recent studies have reported several mutations in the gene encoding SNAP25 as a causative factor for developmental and epileptic encephalopathies of infancy and childhood with diverse clinical manifestations. However, it remains unclear how SNAP25 mutations give rise to these disorders. Here, we show that although structurally clustered mutations in SNAP25 give rise to related synaptic transmission phenotypes, specific alterations in spontaneous neurotransmitter release are a key factor to account for disease heterogeneity. Importantly, we identified a single mutation that augments spontaneous release without altering evoked release, suggesting that aberrant spontaneous release is sufficient to cause disease in humans.
- Published
- 2020
7. Targeting homeostatic synaptic plasticity for treatment of mood disorders
- Author
-
Lisa M. Monteggia and Ege T. Kavalali
- Subjects
0301 basic medicine ,Bipolar Disorder ,Lithium (medication) ,medicine.drug_class ,Biology ,Article ,03 medical and health sciences ,Depressive Disorder, Treatment-Resistant ,0302 clinical medicine ,Antimanic Agents ,Homeostatic plasticity ,medicine ,Animals ,Homeostasis ,Humans ,Depressive Disorder, Major ,Synaptic scaling ,Neuronal Plasticity ,Mood Disorders ,General Neuroscience ,Mood stabilizer ,Cognition ,medicine.disease ,030104 developmental biology ,Mood disorders ,Synaptic plasticity ,Synapses ,Lithium Compounds ,Antidepressant ,Ketamine ,Neuroscience ,Excitatory Amino Acid Antagonists ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Ketamine exerts rapid antidepressant action in depressed and treatment-resistant depressed patients within hours. At the same time, ketamine elicits a unique form of functional synaptic plasticity that shares several attributes and molecular mechanisms with well-characterized forms of homeostatic synaptic scaling. Lithium is a widely used mood stabilizer also proposed to act via synaptic scaling for its antimanic effects. Several studies to date have identified specific forms of homeostatic synaptic plasticity that are elicited by these drugs used to treat neuropsychiatric disorders. In the last two decades, extensive work on homeostatic synaptic plasticity mechanisms have shown that they diverge from classical synaptic plasticity mechanisms that process and store information and thus present a novel avenue for synaptic regulation with limited direct interference with cognitive processes. In this review, we discuss the intersection of the findings from neuropsychiatric treatments and homeostatic plasticity studies to highlight a potentially wider paradigm for treatment advance.
- Published
- 2020
8. Author response: Spontaneous and evoked neurotransmission are partially segregated at inhibitory synapses
- Author
-
Patricia M. Horvath, Ege T. Kavalali, Michelle K Piazza, and Lisa M. Monteggia
- Subjects
Chemistry ,Inhibitory synapses ,Neurotransmission ,Neuroscience - Published
- 2020
9. Decision letter: A role for CIM6P/IGF2 receptor in memory consolidation and enhancement
- Author
-
Kobi Rosenblum and Lisa M. Monteggia
- Subjects
Computer science ,Memory consolidation ,Receptor ,Neuroscience - Published
- 2020
10. The role of eEF2 kinase in the rapid antidepressant actions of ketamine
- Author
-
Kanzo Suzuki and Lisa M. Monteggia
- Subjects
business.industry ,Neurotrophic factors ,Spontaneous synaptic transmission ,Synaptic plasticity ,Medicine ,NMDA receptor ,Major depressive disorder ,Antidepressant ,Long-term potentiation ,AMPA receptor ,business ,medicine.disease ,Neuroscience - Abstract
Major depressive disorder is a prevalent and serious form of mental illness. While traditional antidepressants ameliorate some of the symptoms associated with depression, the onset of action typically takes several weeks leaving severely depressed individuals vulnerable to self-injurious behavior and possibly suicide. There has been a major unmet need for the development of pharmacological therapies that can quickly alleviate symptoms associated with depression. Clinical data shows that a single sub-psychomimetic dose of ketamine, a noncompetitive glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist, has rapid antidepressant responses in patients with treatment-resistant major depressive disorder. We have studied key signaling pathways and synaptic mechanisms underlying the rapid antidepressant action of ketamine. Our studies show ketamine blocks synaptic NMDA receptors involved in spontaneous synaptic transmission, which deactivates calcium/calmodulin-dependent kinase eukaryotic elongation factor 2 kinase (eEF2K), resulting in dephosphorylation of eukaryotic elongation factor 2 (eEF2), and the subsequent desuppression of brain-derived neurotrophic factor (BDNF) protein synthesis in the hippocampus. This signaling pathway then potentiates synaptic α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor responses that results in a novel form of synaptic potentiation which corresponds with antidepressant efficacy. In this chapter, we focus on our studies examining ketamine's action and the instructive role of eEF2K in rapid antidepressant action. Our recent studies highlight eEF2K as a major molecular substrate mediating synaptic plasticity and the rapid antidepressant effects of ketamine.
- Published
- 2020
11. Genetic Dissection of Presynaptic and Postsynaptic BDNF-TrkB Signaling in Synaptic Efficacy of CA3-CA1 Synapses
- Author
-
Lisa M. Monteggia, Ege T. Kavalali, and Pei-Yi Lin
- Subjects
0301 basic medicine ,Tropomyosin receptor kinase B ,Neurotransmission ,Receptors, Presynaptic ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Postsynaptic potential ,Neurotrophic factors ,LTP induction ,medicine ,Animals ,Humans ,Receptor, trkB ,lcsh:QH301-705.5 ,Chemistry ,musculoskeletal, neural, and ocular physiology ,Long-term potentiation ,Synaptic Potentials ,030104 developmental biology ,medicine.anatomical_structure ,lcsh:Biology (General) ,nervous system ,Schaffer collateral ,Synapses ,embryonic structures ,Synaptic plasticity ,Neuroscience ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
SUMMARY Brain-derived neurotrophic factor (BDNF) and its high-affinity receptor, tropomyosin receptor kinase B (TrkB), regulate long-term potentiation (LTP) in the hippocampus, although the sites of BDNF-TrkB receptors in this process are controversial. We used a viral-mediated approach to delete BDNF or TrkB specifically in CA1 and CA3 regions of the Schaffer collateral pathway. Deletion of BDNF in CA3 or CA1 revealed that presynaptic BDNF is involved in LTP induction, while postsynaptic BDNF contributes to LTP maintenance. Similarly, loss of presynaptic or postsynaptic TrkB receptors leads to distinct LTP deficits, with presynaptic TrkB required to maintain LTP, while postsynaptic TrkB is essential for LTP formation. In addition, loss of TrkB in CA3 significantly diminishes release probability, uncovering a role for presynaptic TrkB receptors in basal neurotransmission. Taken together, this direct comparison of presynaptic and postsynaptic BDNF-TrkB reveals insight into BDNF release and TrkB activation sites in hippocampal LTP., In Brief Lin et al. directly compare a role for presynaptic and postsynaptic BDNF and TrkB receptors in hippocampal LTP. They find that LTP induction is mediated by anterograde BDNF-TrkB signaling, while both anterograde and retrograde BDNFTrkB signaling persists presynaptically and postsynaptically for LTP maintenance., Graphical Abstract
- Published
- 2018
12. Convergence of distinct signaling pathways on synaptic scaling to trigger rapid antidepressant action
- Author
-
Ji-Woon Kim, Kanzo Suzuki, Ege T. Kavalali, Elena Nosyreva, and Lisa M. Monteggia
- Subjects
Elongation Factor 2 Kinase ,Male ,Time Factors ,QH301-705.5 ,Retinoic acid ,Hippocampus ,Tretinoin ,Synaptic Transmission ,Article ,General Biochemistry, Genetics and Molecular Biology ,Glutamatergic ,chemistry.chemical_compound ,rapid antidepressant action ,synaptic scaling ,Animals ,Humans ,Biology (General) ,CA1 Region, Hippocampal ,Mice, Knockout ,Neurons ,Neuronal Plasticity ,Synaptic scaling ,Chemistry ,Retinoic Acid Receptor alpha ,eEF2K ,Antidepressive Agents ,RARα ,Mice, Inbred C57BL ,Retinoic acid receptor ,HEK293 Cells ,Synapses ,Antidepressant ,NMDA receptor ,Ketamine ,Signal transduction ,Neuroscience - Abstract
SUMMARY Ketamine is a noncompetitive glutamatergic N-methyl-d-aspartate receptor (NMDAR) antagonist that exerts rapid antidepressant effects. Preclinical studies identify eukaryotic elongation factor 2 kinase (eEF2K) signaling as essential for the rapid antidepressant action of ketamine. Here, we combine genetic, electrophysiological, and pharmacological strategies to investigate the role of eEF2K in synaptic function and find that acute, but not chronic, inhibition of eEF2K activity induces rapid synaptic scaling in the hippocampus. Retinoic acid (RA) signaling also elicits a similar form of rapid synaptic scaling in the hippocampus, which we observe is independent of eEF2K functioni. The RA signaling pathway is not required for ketamine-mediated antidepressant action; however, direct activation of the retinoic acid receptor α (RARα) evokes rapid antidepressant action resembling ketamine. Our findings show that ketamine and RARα activation independently elicit a similar form of multiplicative synaptic scaling that is causal for rapid antidepressant action., Graphical Abstract, In brief Suzuki et al. examine the role of eEF2K and retinoic acid signaling pathways in synaptic plasticity and rapid antidepressant effects. Their study establishes a causal link between synaptic scaling and rapid antidepressant effects and proposes that this form of synaptic plasticity is a key synaptic substrate for rapid antidepressant action.
- Published
- 2021
13. A synaptic locus for TrkB signaling underlying ketamine rapid antidepressant action
- Author
-
Pei-Yi Lin, Ege T. Kavalali, Zhenzhong Ma, Lisa M. Monteggia, and Melissa Mahgoub
- Subjects
Dynamins ,Hippocampus ,Tropomyosin receptor kinase B ,Biology ,Article ,General Biochemistry, Genetics and Molecular Biology ,Mice ,Neurotrophic factors ,Postsynaptic potential ,medicine ,Animals ,Humans ,Receptor, trkB ,Receptor ,CA1 Region, Hippocampal ,Neurons ,Brain-Derived Neurotrophic Factor ,musculoskeletal, neural, and ocular physiology ,Long-term potentiation ,CA3 Region, Hippocampal ,Antidepressive Agents ,Endocytosis ,HEK293 Cells ,medicine.anatomical_structure ,nervous system ,Schaffer collateral ,Synapses ,Antidepressant ,Ketamine ,Neuroscience ,Signal Transduction - Abstract
SUMMARY Ketamine produces rapid antidepressant action in patients with major depression or treatment-resistant depression. Studies have identified brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin receptor kinase B (TrkB), as necessary for the antidepressant effects and underlying ketamine-induced synaptic potentiation in the hippocampus. Here, we delete BDNF or TrkB in presynaptic CA3 or postsynaptic CA1 regions of the Schaffer collateral pathway to investigate the rapid antidepressant action of ketamine. The deletion of Bdnf in CA3 or CA1 blocks the ketamine-induced synaptic potentiation. In contrast, ablation of TrkB only in postsynaptic CA1 eliminates the ketamine-induced synaptic potentiation. We confirm BDNF-TrkB signaling in CA1 is required for ketamine’s rapid behavioral action. Moreover, ketamine application elicits dynamin1-dependent TrkB activation and downstream signaling to trigger rapid synaptic effects. Taken together, these data demonstrate a requirement for BDNF-TrkB signaling in CA1 neurons in ketamine-induced synaptic potentiation and identify a specific synaptic locus in eliciting ketamine’s rapid antidepressant effects., Graphical Abstract, In brief Lin et al. report the essential role of BDNF signaling through postsynaptic TrkB at CA3-CA1 synapses in ketamine’s synaptic potentiation and rapid antidepressant action. These findings establish a strong correlation between TrkB-dependent potentiation at the CA1 synaptic locus and the antidepressant behavioral action of ketamine.
- Published
- 2021
14. A subthreshold synaptic mechanism regulating BDNF expression and resting synaptic strength
- Author
-
Baris Alten, Patricia M. Horvath, Lisa M. Monteggia, Ege T. Kavalali, and Natali L. Chanaday
- Subjects
Transcription, Genetic ,Rest ,Neurotransmission ,Inhibitory postsynaptic potential ,Article ,General Biochemistry, Genetics and Molecular Biology ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Basic Helix-Loop-Helix Transcription Factors ,Animals ,Calcium Signaling ,RNA, Messenger ,Neurotransmitter ,Calcium signaling ,Neurons ,Synaptic scaling ,Chemistry ,Brain-Derived Neurotrophic Factor ,Excitatory Postsynaptic Potentials ,Neural Inhibition ,Gene Expression Regulation ,Inhibitory Postsynaptic Potentials ,Synapses ,Synaptic plasticity ,Excitatory postsynaptic potential ,NMDA receptor ,Neuroscience - Abstract
SUMMARY Recent studies have demonstrated that protein translation can be regulated by spontaneous excitatory neurotransmission. However, the impact of spontaneous neurotransmitter release on gene transcription remains unclear. Here, we study the effects of the balance between inhibitory and excitatory spontaneous neurotransmission on brain-derived neurotrophic factor (BDNF) regulation and synaptic plasticity. Blockade of spontaneous inhibitory events leads to an increase in the transcription of Bdnf and Npas4 through altered synaptic calcium signaling, which can be blocked by antagonism of NMDA receptors (NMDARs) or L-type voltage-gated calcium channels (VGCCs). Transcription is bidirectionally altered by manipulating spontaneous inhibitory, but not excitatory, currents. Moreover, blocking spontaneous inhibitory events leads to multiplicative downscaling of excitatory synaptic strength in a manner that is dependent on both transcription and BDNF signaling. These results reveal a role for spontaneous inhibitory neurotransmission in BDNF signaling that sets excitatory synaptic strength at rest., In brief Horvath et al. study spontaneous neurotransmission to demonstrate a primary role for inhibition in gene transcription and synaptic plasticity. Inhibitory current through GABAARs, but not excitatory current through AMPARs, bi-directionally regulates transcription of Bdnf and Npas4 at rest. Control over transcription of Bdnf enables mIPSC-driven regulation of excitatory synaptic weight., Graphical abstract
- Published
- 2021
15. Impact of DNMT1 and DNMT3a forebrain knockout on depressive- and anxiety like behavior in mice
- Author
-
Michael J. Morris, Elisa S. Na, Anita E. Autry, and Lisa M. Monteggia
- Subjects
DNA (Cytosine-5-)-Methyltransferase 1 ,Male ,0301 basic medicine ,Elevated plus maze ,Mice, 129 Strain ,medicine.drug_class ,Cognitive Neuroscience ,Experimental and Cognitive Psychology ,Anxiety ,Biology ,Anxiolytic ,DNA methyltransferase ,Article ,DNA Methyltransferase 3A ,Mice ,03 medical and health sciences ,Behavioral Neuroscience ,Prosencephalon ,0302 clinical medicine ,medicine ,Animals ,DNA (Cytosine-5-)-Methyltransferases ,Gene knockout ,Prepulse inhibition ,Mice, Knockout ,Mice, Inbred BALB C ,Behavior, Animal ,Depression ,Prepulse Inhibition ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,embryonic structures ,DNA methylation ,Knockout mouse ,Forebrain ,Neuroscience ,030217 neurology & neurosurgery - Abstract
DNA methylation has been shown to impact certain forms of synaptic and behavioral plasticity that have been implicated in the development in psychiatric disorders. DNA methylation is catalyzed by DNA methyltransferase (DNMT) enzymes that continue to be expressed in postmitotic neurons in the forebrain. Using a conditional forebrain knockout of DNMT1 or DNMT3a we assessed the role of these DNMTs in anxiety and depressive-like behavior in mice using an array of behavioral testing paradigms. Forebrain deletion of DNMT1 had anxiolytic and antidepressant-like properties as assessed by elevated plus maze, novelty suppressed feeding, forced swim, and social interaction tests. DNMT3a knockout mice, by contrast, did not exhibit significant behavioral alterations in these tests. Given the putative role of altered DNA methylation patterns in the development of schizophrenia, we also assessed DNMT1 and DNMT3a knockout mice in a prepulse inhibition task and found an enhanced prepulse inhibition of startle in DNMT1 knockouts relative to wild type mice, with no change evident in DNMT3a knockout mice. Our data suggest that DNMT1 and DNMT3a are distinctly involved in affective behavior and that DNMT1 may ultimately represent a potential target for treatment of certain affective behavioral disorders.
- Published
- 2016
16. Spontaneous and evoked neurotransmission are partially segregated at inhibitory synapses
- Author
-
Patricia M. Horvath, Lisa M. Monteggia, Ege T. Kavalali, and Michelle K Piazza
- Subjects
QH301-705.5 ,Science ,Neurotransmission ,Hippocampal formation ,In Vitro Techniques ,Inhibitory postsynaptic potential ,Synaptic vesicle ,Hippocampus ,Synaptic Transmission ,General Biochemistry, Genetics and Molecular Biology ,GABA Antagonists ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Glutamatergic ,Animals ,Biology (General) ,GABAergic Neurons ,GABAergic neurotransmission ,Cells, Cultured ,General Immunology and Microbiology ,spontaneous release ,General Neuroscience ,Neural Inhibition ,General Medicine ,Receptors, GABA-A ,Electric Stimulation ,picrotoxin ,chemistry ,Inhibitory Postsynaptic Potentials ,Excitatory postsynaptic potential ,Medicine ,GABAergic ,Rat ,Female ,Neuroscience ,Picrotoxin ,Research Article - Abstract
Synaptic transmission is initiated via spontaneous or action-potential evoked fusion of synaptic vesicles. At excitatory synapses, glutamatergic receptors activated by spontaneous and evoked neurotransmission are segregated. Although inhibitory synapses also transmit signals spontaneously or in response to action potentials, they differ from excitatory synapses in both structure and function. Therefore, we hypothesized that inhibitory synapses may have different organizing principles. We report picrotoxin, a GABAAR antagonist, blocks neurotransmission in a use-dependent manner at rat hippocampal synapses and therefore can be used to interrogate synaptic properties. Using this tool, we uncovered partial segregation of inhibitory spontaneous and evoked neurotransmission. We found up to 40% of the evoked response is mediated through GABAARs which are only activated by evoked neurotransmission. These data indicate GABAergic spontaneous and evoked neurotransmission processes are partially non-overlapping, suggesting they may serve divergent roles in neuronal signaling.
- Published
- 2019
17. TrkB Signaling in Dorsal Raphe Nucleus is Essential for Antidepressant Efficacy and Normal Aggression Behavior
- Author
-
Megumi Adachi, Anita E. Autry, Kanzo Suzuki, Lisa M. Monteggia, and Melissa Mahgoub
- Subjects
Dorsal Raphe Nucleus ,Male ,0301 basic medicine ,Poison control ,Tropomyosin receptor kinase B ,Animals, Genetically Modified ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Dorsal raphe nucleus ,Limbic system ,Neurotrophic factors ,Neuroplasticity ,medicine ,Animals ,Receptor, trkB ,Pharmacology ,Behavior, Animal ,Depression ,Brain-Derived Neurotrophic Factor ,musculoskeletal, neural, and ocular physiology ,Antidepressive Agents ,Disease Models, Animal ,Psychiatry and Mental health ,030104 developmental biology ,medicine.anatomical_structure ,nervous system ,Antidepressant ,Original Article ,Psychopharmacology ,Psychology ,Neuroscience ,030217 neurology & neurosurgery ,Signal Transduction - Abstract
Brain-derived neurotrophic factor (BDNF) and its high affinity receptor, tropomyosin receptor kinase B (TrkB), have important roles in neural plasticity and are required for antidepressant efficacy. Studies examining the role of BDNF-TrkB signaling in depression and antidepressant efficacy have largely focused on the limbic system, leaving it unclear whether this signaling is important in other brain regions. BDNF and TrkB are both highly expressed in the dorsal raphe nucleus (DRN), a brain region that has been suggested to have a role in depression and antidepressant action, although it is unknown whether BDNF and TrkB in the dorsal raphe nucleus are involved in these processes. We combined the adeno-associated virus (AAV) with the Cre-loxP site-specific recombination system to selectively knock down either Bdnf or TrkB in the DRN. These mice were then characterized in several behavioral paradigms including measures of depression-related behavior and antidepressant efficacy. We show that knockdown of TrkB, but not Bdnf, in the DRN results in loss of antidepressant efficacy and increased aggression-related behavior. We also show that knockdown of TrkB or Bdnf in this brain region does not have an impact on weight, activity levels, anxiety, or depression-related behaviors. These data reveal a critical role for TrkB signaling in the DRN in mediating antidepressant responses and normal aggression behavior. The results also suggest a non-cell autonomous role for BDNF in the DRN in mediating antidepressant efficacy.
- Published
- 2016
18. Effects of a ketamine metabolite on synaptic NMDAR function
- Author
-
Kanzo Suzuki, Kevin W. Hunt, Elena Nosyreva, Lisa M. Monteggia, and Ege T. Kavalali
- Subjects
0301 basic medicine ,Multidisciplinary ,Hydroxynorketamine ,business.industry ,Metabolite ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,Text mining ,chemistry ,Medicine ,NMDA receptor ,Ketamine ,business ,Neuroscience ,030217 neurology & neurosurgery ,Function (biology) ,medicine.drug - Published
- 2017
19. Correction: D-cycloserine improves synaptic transmission in an animal mode of Rett syndrome
- Author
-
Héctor De Jesús-Cortés, Yasemin Onder, Elisa S. Na, Andrew A. Pieper, Vijayashree Ramesh, Arlene Martinez-Rivera, Zeeba D. Kabir, Anjali M. Rajadhyaksha, Lisa M. Monteggia, and Jieqi Wang
- Subjects
Male ,Apnea ,Methyl-CpG-Binding Protein 2 ,D-cycloserine ,lcsh:Medicine ,Rett syndrome ,Mice, Transgenic ,Neurotransmission ,Hippocampus ,Synaptic Transmission ,Mice ,Tremor ,medicine ,Rett Syndrome ,Animals ,Muscle Strength ,lcsh:Science ,Gait ,Multidisciplinary ,business.industry ,Brain-Derived Neurotrophic Factor ,lcsh:R ,Correction ,medicine.disease ,Corpus Striatum ,Disease Models, Animal ,Cycloserine ,lcsh:Q ,business ,Neuroscience ,Locomotion ,Brain Stem - Abstract
Rett syndrome (RTT), a leading cause of intellectual disability in girls, is predominantly caused by mutations in the X-linked gene MECP2. Disruption of Mecp2 in mice recapitulates major features of RTT, including neurobehavioral abnormalities, which can be reversed by re-expression of normal Mecp2. Thus, there is reason to believe that RTT could be amenable to therapeutic intervention throughout the lifespan of patients after the onset of symptoms. A common feature underlying neuropsychiatric disorders, including RTT, is altered synaptic function in the brain. Here, we show that Mecp2tm1.1Jae/y mice display lower presynaptic function as assessed by paired pulse ratio, as well as decreased long term potentiation (LTP) at hippocampal Schaffer-collateral-CA1 synapses. Treatment of Mecp2tm1.1Jae/y mice with D-cycloserine (DCS), an FDA-approved analog of the amino acid D-alanine with antibiotic and glycinergic activity, corrected the presynaptic but not LTP deficit without affecting deficient hippocampal BDNF levels. DCS treatment did, however, partially restore lower BDNF levels in the brain stem and striatum. Thus, treatment with DCS may mitigate the severity of some of the neurobehavioral symptoms experienced by patients with Rett syndrome.
- Published
- 2018
20. Selective role for DNMT3a in learning and memory
- Author
-
Lisa M. Monteggia, Michael J. Morris, Elisa S. Na, and Megumi Adachi
- Subjects
Methyltransferase ,Memory, Episodic ,Cognitive Neuroscience ,Conditioning, Classical ,Long-Term Potentiation ,Experimental and Cognitive Psychology ,Real-Time Polymerase Chain Reaction ,Hippocampus ,environment and public health ,Article ,DNA Methyltransferase 3A ,Behavioral Neuroscience ,Cytosine nucleotide ,Memory ,Animals ,Learning ,DNA (Cytosine-5-)-Methyltransferases ,Episodic memory ,Gene knockout ,Mice, Knockout ,Mice, Inbred BALB C ,Long-term potentiation ,Associative learning ,Mice, Inbred C57BL ,Repressor Proteins ,embryonic structures ,Synaptic plasticity ,Knockout mouse ,Psychology ,Neuroscience - Abstract
Methylation of cytosine nucleotides is governed by DNA methyltransferases (DNMTs) that establish de novo DNA methylation patterns in early embryonic development (e.g., DNMT3a and DNMT3b) or maintain those patterns on hemimethylated DNA in dividing cells (e.g., DNMT1). DNMTs continue to be expressed at high levels in mature neurons, however their impact on neuronal function and behavior are unclear. To address this issue we examined DNMT1 and DNMT3a expression following associative learning. We also generated forebrain specific conditional Dnmt1 or Dnmt3a knockout mice and characterized them in learning and memory paradigms as well as for alterations in long-term potentiation (LTP) and synaptic plasticity. Here, we report that experience in an associative learning task impacts expression of Dnmt3a, but not Dnmt1, in brain areas that mediate learning of this task. We also found that Dnmt3a knockout mice, and not Dnmt1 knockouts have synaptic alterations as well as learning deficits on several associative and episodic memory tasks. These findings indicate that the de novo DNA methylating enzyme DNMT3a in postmitotic neurons is necessary for normal memory formation and its function cannot be substituted by the maintenance DNA methylating enzyme DNMT1.
- Published
- 2014
21. D-cycloserine improves synaptic transmission in an animal mode of Rett syndrome
- Author
-
Arlene Martinez-Rivera, Andrew A. Pieper, Héctor De Jesús-Cortés, Jieqi Wang, Lisa M. Monteggia, Anjali M. Rajadhyaksha, Elisa S. Na, Yasemin Onder, Vijayashree Ramesh, and Zeeba D. Kabir
- Subjects
0301 basic medicine ,Pulmonology ,Physiology ,Apnea ,lcsh:Medicine ,Hippocampus ,Striatum ,Hippocampal formation ,Mice ,0302 clinical medicine ,Medicine and Health Sciences ,Medicine ,Enzyme-Linked Immunoassays ,lcsh:Science ,Mammals ,Multidisciplinary ,Respiration ,Brain ,Long-term potentiation ,Animal Models ,Experimental Organism Systems ,Breathing ,Vertebrates ,Anatomy ,Gait Analysis ,Brainstem ,Research Article ,congenital, hereditary, and neonatal diseases and abnormalities ,Neural facilitation ,Rett syndrome ,Mouse Models ,Neurotransmission ,Research and Analysis Methods ,Rodents ,MECP2 ,03 medical and health sciences ,Model Organisms ,Animals ,Immunoassays ,business.industry ,Biological Locomotion ,lcsh:R ,Organisms ,Biology and Life Sciences ,medicine.disease ,Neostriatum ,030104 developmental biology ,nervous system ,Amniotes ,Immunologic Techniques ,lcsh:Q ,business ,Physiological Processes ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Rett syndrome (RTT), a leading cause of intellectual disability in girls, is predominantly caused by mutations in the X-linked gene MECP2. Disruption of Mecp2 in mice recapitulates major features of RTT, including neurobehavioral abnormalities, which can be reversed by re-expression of normal Mecp2. Thus, there is reason to believe that RTT could be amenable to therapeutic intervention throughout the lifespan of patients after the onset of symptoms. A common feature underlying neuropsychiatric disorders, including RTT, is altered synaptic function in the brain. Here, we show that Mecp2tm1.1Jae/y mice display lower presynaptic function as assessed by paired pulse ratio, as well as decreased long term potentiation (LTP) at hippocampal Schaffer-collateral-CA1 synapses. Treatment of Mecp2tm1.1Jae/y mice with D-cycloserine (DCS), an FDA-approved analog of the amino acid D-alanine with antibiotic and glycinergic activity, corrected the presynaptic but not LTP deficit without affecting deficient hippocampal BDNF levels. DCS treatment did, however, partially restore lower BDNF levels in the brain stem and striatum. Thus, treatment with DCS may mitigate the severity of some of the neurobehavioral symptoms experienced by patients with Rett syndrome.
- Published
- 2017
22. Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling
- Author
-
Erinn S Gideons, Pei-Yi Lin, Melissa Mahgoub, Ege T Kavalali, and Lisa M Monteggia
- Subjects
0301 basic medicine ,Patch-Clamp Techniques ,Mouse ,bdnf ,Lithium (medication) ,QH301-705.5 ,Science ,Tropomyosin receptor kinase B ,AMPA receptor ,Neurotransmission ,Hippocampus ,Synaptic Transmission ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,mania ,0302 clinical medicine ,Antimanic Agents ,Postsynaptic potential ,Homeostatic plasticity ,dynamin ,medicine ,Animals ,Receptor, trkB ,endocytosis ,Biology (General) ,Neurons ,Brain-derived neurotrophic factor ,General Immunology and Microbiology ,Chemistry ,Brain-Derived Neurotrophic Factor ,General Neuroscience ,General Medicine ,3. Good health ,Mice, Inbred C57BL ,030104 developmental biology ,Receptors, Glutamate ,nervous system ,lithium ,Excitatory postsynaptic potential ,Medicine ,Neuroscience ,030217 neurology & neurosurgery ,Research Article ,medicine.drug - Abstract
Lithium is widely used as a treatment for Bipolar Disorder although the molecular mechanisms that underlie its therapeutic effects are under debate. In this study, we show brain-derived neurotrophic factor (BDNF) is required for the antimanic-like effects of lithium but not the antidepressant-like effects in mice. We performed whole cell patch clamp recordings of hippocampal neurons to determine the impact of lithium on synaptic transmission that may underlie the behavioral effects. Lithium produced a significant decrease in α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated miniature excitatory postsynaptic current (mEPSC) amplitudes due to postsynaptic homeostatic plasticity that was dependent on BDNF and its receptor tropomyosin receptor kinase B (TrkB). The decrease in AMPAR function was due to reduced surface expression of GluA1 subunits through dynamin-dependent endocytosis. Collectively, these findings demonstrate a requirement for BDNF in the antimanic action of lithium and identify enhanced dynamin-dependent endocytosis of AMPARs as a potential mechanism underlying the therapeutic effects of lithium. DOI: http://dx.doi.org/10.7554/eLife.25480.001, eLife digest Nerve cells, or neurons, communicate with each other by releasing chemical messengers that bind to and activate receptor proteins on the surface of the other cells. The chemicals affect the connections between neurons, and many diseases – including bipolar disorder – are related to there being too much or too little of these chemicals in the brain. Patients with bipolar disorder experience periods of both depression and mania. During a manic episode, affected individuals typically feel elated and have more energy than usual despite needing less sleep, but also can also be irritable and impulsive. The exact cause of bipolar disorder is unknown. Patients with bipolar disorder often have low levels of a protein called brain-derived neurotrophic factor, or BDNF for short, which plays an essential role in keeping the brain healthy, and may also regulate the connections between neurons. One of the main treatments for bipolar disorder, a mood stabilizer called lithium, has also been linked to BDNF in previous studies; however, the details of the interaction were not clear. Gideons et al. studied how lithium works by feeding mice food pellets that contained lithium. After a few weeks, the mice had concentrations of lithium in their blood comparable to those of people taking the drug, as well as increased levels of BDNF in the brain. Gideons et al. then examined if BDNF was needed for the lithium’s ability to treat manic episodes. Mice exposed to another drug, amphetamine, normally move around a lot, mimicking the increased energy of someone with mania. As expected, feeding normal mice lithium blocked this effect of amphetamine, but feeding lithium to mutant mice that lack BDNF did not. This indicates that BDNF is indeed needed for the antimanic effect of lithium. Further experiments showed that BDNF is not needed for lithium’s antidepressant effect. By studying the animals’ brains, Gideons et al. went on to show that the lithium-fed mice had weaker connections between their neurons than mice that had eaten standard food. In the lithium-fed mice, many of the receptor proteins had been reabsorbed back into the neurons, lowering the ability of neurons to communicate with one another. This process depended on BDNF, suggesting that this protein is essential for lithium to suppress the connections between neurons. Taken together, these results reveal that the effects of lithium on both an animal’s brain and its behavior rely on BDNF. This knowledge should make it easier to develop new strategies and identifying new molecularly specific targets for treating bipolar disorder as well as other neuropsychiatric diseases. DOI: http://dx.doi.org/10.7554/eLife.25480.002
- Published
- 2017
23. Author response: Chronic lithium treatment elicits its antimanic effects via BDNF-TrkB dependent synaptic downscaling
- Author
-
Lisa M. Monteggia, Erinn S. Gideons, Pei-Yi Lin, Ege T. Kavalali, and Melissa Mahgoub
- Subjects
Chemistry ,Tropomyosin receptor kinase B ,Chronic lithium ,Neuroscience - Published
- 2017
24. Loss of Doc2-Dependent Spontaneous Neurotransmission Augments Glutamatergic Synaptic Strength
- Author
-
Denise M.O. Ramirez, Devon C. Crawford, Ege T. Kavalali, Lisa M. Monteggia, Natali L. Chanaday, and Brent Trauterman
- Subjects
0301 basic medicine ,Nervous system ,Male ,Postsynaptic Current ,Action Potentials ,Glutamic Acid ,Nerve Tissue Proteins ,Neurotransmission ,Biology ,Inhibitory postsynaptic potential ,Synaptic Transmission ,Rats, Sprague-Dawley ,03 medical and health sciences ,Glutamatergic ,0302 clinical medicine ,Postsynaptic potential ,medicine ,Animals ,Cells, Cultured ,Research Articles ,Neurotransmitter Agents ,Synaptic scaling ,General Neuroscience ,Calcium-Binding Proteins ,Excitatory Postsynaptic Potentials ,Rats ,030104 developmental biology ,medicine.anatomical_structure ,Synapses ,Excitatory postsynaptic potential ,Female ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Action potential-evoked vesicle fusion comprises the majority of neurotransmission within chemical synapses, but action potential-independent spontaneous neurotransmission also contributes to the collection of signals sent to the postsynaptic cell. Previous work has implicated spontaneous neurotransmission in homeostatic synaptic scaling, but few studies have selectively manipulated spontaneous neurotransmission without substantial changes in evoked neurotransmission to study this function in detail. Here we used a quadruple knockdown strategy to reduce levels of proteins within the soluble calcium-binding double C2 domain (Doc2)-like protein family to selectively reduce spontaneous neurotransmission in cultured mouse and rat neurons. Activity-evoked responses appear normal while both excitatory and inhibitory spontaneous events exhibit reduced frequency. Excitatory miniature postsynaptic currents (mEPSCs), but not miniature inhibitory postsynaptic currents (mIPSCs), increase in amplitude after quadruple knockdown. This increase in synaptic efficacy correlates with reduced phosphorylation levels of eukaryotic elongation factor 2 and also requires the presence of elongation factor 2 kinase. Together, these data suggest that spontaneous neurotransmission independently contributes to the regulation of synaptic efficacy, and action potential-evoked and spontaneous neurotransmission can be segregated at least partially on a molecular level.SIGNIFICANCE STATEMENT Action potential-evoked and spontaneous neurotransmission have been observed in nervous system circuits as long as methods have existed to measure them. Despite being well studied, controversy still remains about whether these forms of neurotransmission are regulated independently on a molecular level or whether they are simply a continuum of neurotransmission modes. In this study, members of the Doc2 family of presynaptic proteins were eliminated, which caused a reduction in spontaneous neurotransmission, whereas action potential-evoked neurotransmission remained relatively normal. This protein loss also caused an increase in synaptic strength, suggesting that spontaneous neurotransmission is able to communicate independently with the postsynaptic neuron and trigger downstream signaling cascades that regulate the synaptic state.
- Published
- 2017
25. Selective molecular impairment of spontaneous neurotransmission modulates synaptic efficacy
- Author
-
Ege T. Kavalali, Denise M.O. Ramirez, Devon C. Crawford, Lisa M. Monteggia, and Brent Trauterman
- Subjects
Elongation Factor 2 Kinase ,Male ,0301 basic medicine ,Science ,Glutamic Acid ,General Physics and Astronomy ,Neurotransmission ,Receptors, N-Methyl-D-Aspartate ,Synaptic Transmission ,Synaptic vesicle ,Article ,General Biochemistry, Genetics and Molecular Biology ,R-SNARE Proteins ,Rats, Sprague-Dawley ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Postsynaptic potential ,Animals ,Neurotransmitter ,Cells, Cultured ,Mice, Knockout ,Neurons ,Multidisciplinary ,Glutamate receptor ,Long-term potentiation ,General Chemistry ,Glutamic acid ,Qb-SNARE Proteins ,3. Good health ,030104 developmental biology ,chemistry ,Synapses ,NMDA receptor ,Female ,RNA Interference ,Neuroscience ,030217 neurology & neurosurgery - Abstract
Recent studies suggest that stimulus-evoked and spontaneous neurotransmitter release processes are mechanistically distinct. Here we targeted the non-canonical synaptic vesicle SNAREs Vps10p-tail-interactor-1a (vti1a) and vesicle-associated membrane protein 7 (VAMP7) to specifically inhibit spontaneous release events and probe whether these events signal independently of evoked release to the postsynaptic neuron. We found that loss of vti1a and VAMP7 impairs spontaneous high-frequency glutamate release and augments unitary event amplitudes by reducing postsynaptic eukaryotic elongation factor 2 kinase (eEF2K) activity subsequent to the reduction in N-methyl-D-aspartate receptor (NMDAR) activity. Presynaptic, but not postsynaptic, loss of vti1a and VAMP7 occludes NMDAR antagonist-induced synaptic potentiation in an intact circuit, confirming the role of these vesicular SNAREs in setting synaptic strength. Collectively, these results demonstrate that spontaneous neurotransmission signals independently of stimulus-evoked release and highlight its role as a key regulator of postsynaptic efficacy., Emerging evidence suggests that spontaneous neurotransmitter release contributes to the maintenance of synaptic efficacy. Here the authors selectively reduce spontaneous glutamatergic transmission while leaving the stimulus-evoked responses intact and show that this leads to homeostatic scaling at the postsynaptic side in cultured neurons and alters synaptic plasticity in acute brain slices.
- Published
- 2017
26. GABAA Receptor Antagonism Ameliorates Behavioral and Synaptic Impairments Associated with MeCP2 Overexpression
- Author
-
Michael J. Morris, Lisa M. Monteggia, Elisa S. Na, and Erika D. Nelson
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Methyl-CpG-Binding Protein 2 ,MECP2 duplication syndrome ,Mice, Transgenic ,Rett syndrome ,Neurotransmission ,Biology ,Hippocampus ,MECP2 ,Mice ,Neurodevelopmental disorder ,Internal medicine ,mental disorders ,Neuroplasticity ,medicine ,Animals ,Picrotoxin ,GABA-A Receptor Antagonists ,Pharmacology ,Neuronal Plasticity ,Behavior, Animal ,GABAA receptor ,medicine.disease ,nervous system diseases ,Mice, Inbred C57BL ,Disease Models, Animal ,Psychiatry and Mental health ,Endocrinology ,Synaptic plasticity ,Mental Retardation, X-Linked ,Original Article ,Neuroscience - Abstract
Methyl-CpG-binding protein 2 (MeCP2) is a ubiquitously expressed transcriptional regulator with functional importance in the central nervous system. Loss-of-function mutations in MECP2 results in the neurodevelopmental disorder, Rett syndrome, whereas increased expression levels are associated with the neurological disorder, MECP2 duplication syndrome. Previous characterization of a mouse line overexpressing Mecp2 demonstrated that this model recapitulated key behavioral features of MECP2 duplication syndrome with specific deficits in synaptic plasticity and neurotransmission. Alterations in excitation/inhibition balance have been suggested to underlie neurodevelopmental disorders with recent data suggesting that picrotoxin (PTX), a GABAA receptor antagonist, rescues certain behavioral and synaptic phenotypes in a mouse model of Down syndrome. We therefore examined whether a similar treatment regimen would impact the behavioral and synaptic phenotypes in a mouse model of MECP2 duplication syndrome. We report that chronic treatment with low doses of PTX ameliorates specific behavioral phenotypes, including motor coordination, episodic memory impairments, and synaptic plasticity deficits. These findings suggest that GABAA receptor antagonists may offer a possible therapeutic target for the treatment of MECP2 duplication syndrome.
- Published
- 2014
27. mTOR complexes in neurodevelopmental and neuropsychiatric disorders
- Author
-
Mauro Costa-Mattioli and Lisa M. Monteggia
- Subjects
Mtor signaling ,Extramural ,Mental Disorders ,TOR Serine-Threonine Kinases ,General Neuroscience ,Synaptic efficacy ,mTORC1 ,Biology ,mTORC2 ,biology.protein ,Animals ,Humans ,Premovement neuronal activity ,Nervous System Diseases ,Neuroscience ,Mechanistic target of rapamycin ,PI3K/AKT/mTOR pathway ,Signal Transduction - Abstract
The mechanistic target of rapamycin (mTOR) acts as a highly conserved signaling "hub" that integrates neuronal activity and a variety of synaptic inputs. mTOR is found in two functionally distinct complexes, mTORC1 and mTORC2, that crucially control long-term synaptic efficacy and memory storage. Dysregulation of mTOR signaling is associated with neurodevelopmental and neuropsychiatric disorders. In this Review, we describe the most recent advances in studies of mTOR signaling in the brain and the possible mechanisms underlying the many different functions of the mTOR complexes in neurological diseases. In addition, we discuss the medical relevance of these findings.
- Published
- 2013
28. Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
- Author
-
Ege T. Kavalali and Lisa M. Monteggia
- Subjects
medicine.drug_class ,Psychotomimetic ,medicine.disease ,Receptor antagonist ,Psychiatry and Mental health ,Glutamatergic ,Anesthesia ,medicine ,Major depressive disorder ,NMDA receptor ,Antidepressant ,Ketamine ,Psychology ,Neuroscience ,Ionotropic effect ,medicine.drug - Abstract
Recent clinical studies have demonstrated that a single subpsychotomimetic dose of ketamine, an ionotropic glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist, produces a rapid antidepressant response in patients with major depressive disorder, with effects lasting up to 2 weeks. Despite enthusiasm about this unexpected efficacy of ketamine, its widespread use as a fast-acting antidepressant in routine clinical settings is curtailed by its abuse potential as well as possible psychotomimetic effects. However, the ability of ketamine to produce a rapid and long-lasting antidepressant response in patients with depression provides a unique opportunity for investigation of mechanisms that mediate these clinically relevant behavioral effects. From a mechanistic perspective, it is easy to imagine how activation of NMDA receptors may trigger cellular and behavioral responses; it is relatively more difficult, however, to envision how transient blockade of one of the key pathways for neuronal communicatio...
- Published
- 2012
29. The Impact of MeCP2 Loss- or Gain-of-Function on Synaptic Plasticity
- Author
-
Ege T. Kavalali, Lisa M. Monteggia, Erika D. Nelson, and Elisa S. Na
- Subjects
Pharmacology ,congenital, hereditary, and neonatal diseases and abnormalities ,Neuronal Plasticity ,Methyl-CpG-Binding Protein 2 ,MECP2 duplication syndrome ,Rett syndrome ,Long-term potentiation ,Biology ,medicine.disease ,Cell morphology ,Synaptic Transmission ,nervous system diseases ,MECP2 ,Psychiatry and Mental health ,Synaptic fatigue ,Synapses ,mental disorders ,Synaptic plasticity ,Metaplasticity ,Neuropsychopharmacology Reviews ,Rett Syndrome ,medicine ,Animals ,Humans ,Neuroscience - Abstract
Methyl-CpG-binding protein 2 (MeCP2) is a transcriptional regulator of gene expression that is an important epigenetic factor in the maintenance and development of the central nervous system. The neurodevelopmental disorders Rett syndrome and MECP2 duplication syndrome arise from loss-of-function and gain-of-function alterations in MeCP2 expression, respectively. Several animal models have been developed to recapitulate the symptoms of Rett syndrome and MECP2 duplication syndrome. Cell morphology, neurotransmission, and cellular processes that support learning and memory are compromised as a result of MeCP2 loss- or gain-of-function. Interestingly, loss-of-MeCP2 function and MeCP2 overexpression trigger diametrically opposite changes in synaptic transmission. These findings indicate that the precise regulation of MeCP2 expression is a key requirement for the maintenance of synaptic and neuronal homeostasis and underscore its importance in central nervous system function. This review highlights the functional role of MeCP2 in the brain as a regulator of synaptic and neuronal plasticity as well as its etiological role in the development of Rett syndrome and MECP2 duplication syndrome.
- Published
- 2012
30. Brain-Derived Neurotrophic Factor and Neuropsychiatric Disorders
- Author
-
Anita E. Autry and Lisa M. Monteggia
- Subjects
media_common.quotation_subject ,Central nervous system ,Rett syndrome ,Drug Delivery Systems ,Neuroplasticity ,medicine ,Animals ,Humans ,Review Articles ,media_common ,Pharmacology ,Brain-derived neurotrophic factor ,Neuronal Plasticity ,business.industry ,Brain-Derived Neurotrophic Factor ,Mental Disorders ,Addiction ,medicine.disease ,Antidepressive Agents ,medicine.anatomical_structure ,nervous system ,Drug development ,Schizophrenia ,Drug Design ,Molecular Medicine ,Major depressive disorder ,Nervous System Diseases ,business ,Neuroscience ,Antipsychotic Agents - Abstract
Brain derived neurotrophic factor (BDNF) is the most prevalent growth factor in the central nervous system (CNS). It is essential for the development of the CNS and for neuronal plasticity. Because BDNF plays a crucial role in development and plasticity of the brain, it is widely implicated in psychiatric diseases. This review provides a summary of clinical and preclinical evidence for the involvement of this ubiquitous growth factor in major depressive disorder, schizophrenia, addiction, Rett syndrome, as well as other psychiatric and neurodevelopmental diseases. In addition, the review includes a discussion of the role of BDNF in the mechanism of action of pharmacological therapies currently used to treat these diseases, such antidepressants and antipsychotics. The review also covers a critique of experimental therapies such as BDNF mimetics and discusses the value of BDNF as a target for future drug development.
- Published
- 2012
31. A Mouse Model forMeCP2Duplication Syndrome: MeCP2 Overexpression Impairs Learning and Memory and Synaptic Transmission
- Author
-
Elisa S. Na, Anita E. Autry, Megumi Adachi, Lisa M. Monteggia, Melissa Mahgoub, Ege T. Kavalali, and Erika D. Nelson
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,Methyl-CpG-Binding Protein 2 ,MECP2 duplication syndrome ,Mice, Transgenic ,tau Proteins ,Rett syndrome ,Hippocampal formation ,Neurotransmission ,Biology ,Synaptic Transmission ,Article ,MECP2 ,Mice ,Excitatory synapse ,Memory ,Gene Duplication ,mental disorders ,Rett Syndrome ,medicine ,Animals ,Learning ,General Neuroscience ,Long-term potentiation ,Syndrome ,medicine.disease ,nervous system diseases ,Mice, Inbred C57BL ,Disease Models, Animal ,Gene Expression Regulation ,Synaptic plasticity ,Neuroscience - Abstract
Rett syndrome andMECP2duplication syndrome are neurodevelopmental disorders that arise from loss-of-function and gain-of-function alterations in methyl-CpG binding protein 2 (MeCP2) expression, respectively. Although there have been studies examining MeCP2 loss of function in animal models, there is limited information on MeCP2 overexpression in animal models. Here, we characterize a mouse line with MeCP2 overexpression restricted to neurons (Tau–Mecp2). This MeCP2 overexpression line shows motor coordination deficits, heightened anxiety, and impairments in learning and memory that are accompanied by deficits in long-term potentiation and short-term synaptic plasticity. Whole-cell voltage-clamp recordings of cultured hippocampal neurons fromTau–Mecp2mice reveal augmented frequency of miniature EPSCs with no change in miniature IPSCs, indicating that overexpression of MeCP2 selectively impacts excitatory synapse function. Moreover, we show that alterations in transcriptional repression mechanisms underlie the synaptic phenotypes in hippocampal neurons from theTau–Mecp2mice. These results demonstrate that theTau–Mecp2mouse line recapitulates many key phenotypes ofMECP2duplication syndrome and support the use of these mice to further study this devastating disorder.
- Published
- 2012
32. BDNF — a key transducer of antidepressant effects
- Author
-
Carl Björkholm and Lisa M. Monteggia
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Tropomyosin receptor kinase B ,AMPA receptor ,Hippocampus ,Article ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,Mice ,0302 clinical medicine ,Neurotrophic factors ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology ,Brain-derived neurotrophic factor ,Depression ,Brain-Derived Neurotrophic Factor ,Long-term potentiation ,Antidepressive Agents ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,nervous system ,Synaptic plasticity ,NMDA receptor ,Antidepressant ,Psychology ,Neuroscience ,030217 neurology & neurosurgery - Abstract
How do antidepressants elicit an antidepressant response? Here, we review accumulating evidence that the neurotrophin brain-derived neurotrophic factor (BDNF) serves as a transducer, acting as the link between the antidepressant drug and the neuroplastic changes that result in the improvement of the depressive symptoms. Over the last decade several studies have consistently highlighted BDNF as a key player in antidepressant action. An increase in hippocampal and cortical expression of BDNF mRNA parallels the antidepressant-like response of conventional antidepressants such as SSRIs. Subsequent studies showed that a single bilateral infusion of BDNF into the ventricles or directly into the hippocampus is sufficient to induce a relatively rapid and sustained antidepressant-like effect. Importantly, the antidepressant-like response to conventional antidepressants is attenuated in mice where the BDNF signaling has been disrupted by genetic manipulations. Low dose ketamine, which has been found to induce a rapid antidepressant effect in patients with treatment-resistant depression, is also dependent on increased BDNF signaling. Ketamine transiently increases BDNF translation in hippocampus, leading to enhanced synaptic plasticity and synaptic strength. Ketamine has been shown to increase BDNF translation by blocking NMDA receptor activity at rest, thereby inhibiting calcium influx and subsequently halting eukaryotic elongation factor 2 (eEF2) kinase leading to a desuppression of protein translation, including BDNF translation. The antidepressant-like response of ketamine is abolished in BDNF and TrkB conditional knockout mice, eEF2 kinase knockout mice, in mice carrying the BDNF met/met allele, and by intra-cortical infusions of BDNF-neutralizing antibodies. In summary, current data suggests that conventional antidepressants and ketamine mediate their antidepressant-like effects by increasing BDNF in forebrain regions, in particular the hippocampus, making BDNF an essential determinant of antidepressant efficacy.
- Published
- 2015
33. Selective impact of MeCP2 and associated histone deacetylases on the dynamics of evoked excitatory neurotransmission
- Author
-
Erika D. Nelson, Ege T. Kavalali, Manjot Bal, and Lisa M. Monteggia
- Subjects
Male ,Methyl-CpG-Binding Protein 2 ,Physiology ,Histone Deacetylase 2 ,Histone Deacetylase 1 ,Rett syndrome ,Neurotransmission ,Biology ,Inhibitory postsynaptic potential ,Hippocampus ,Synaptic Transmission ,MECP2 ,Mice ,Neuroplasticity ,medicine ,Animals ,Cells, Cultured ,Mice, Knockout ,Neurons ,Neuronal Plasticity ,Histone deacetylase 2 ,General Neuroscience ,Articles ,medicine.disease ,Excitatory postsynaptic potential ,Autism ,Neuroscience - Abstract
An imbalance between the strengths of excitatory and inhibitory synaptic inputs has been proposed as the cellular basis of autism and related neurodevelopmental disorders. Previous studies examining spontaneous levels of excitatory and inhibitory neurotransmission in the forebrain regions of methyl-CpG-binding protein 2 ( Mecp2) mutant mice, models of the autism spectrum disorder Rett syndrome, have identified a decrease in excitatory drive, in some cases coupled with an increase in inhibitory synaptic strength, as a major source of this imbalance. Here, we reevaluated this question by examining the short-term dynamics of evoked neurotransmission between hippocampal neurons cultured from MeCP2 knockout mice and found a marked increase in evoked excitatory neurotransmission that is consistent with an increase in presynaptic release probability. This increase in evoked excitatory drive was not matched with alterations in evoked inhibitory neurotransmission. Moreover, we observed similar excitatory drive specific changes after the loss of key histone deacetylases (histone deacetylase 1 and 2) that form a complex with MeCP2 and mediate transcriptional regulation. These findings suggest a distinct role for MeCP2 and its cofactors in the regulation of evoked excitatory neurotransmission compared with their essential role in basal synaptic activity.
- Published
- 2011
34. Epigenetics in the mature mammalian brain: Effects on behavior and synaptic transmission
- Author
-
Erika D. Nelson and Lisa M. Monteggia
- Subjects
Neurons ,Epigenetic regulation of neurogenesis ,Behavior, Animal ,Cognitive Neuroscience ,Brain ,Experimental and Cognitive Psychology ,DNA Methylation ,Biology ,Neurotransmission ,Synaptic Transmission ,Article ,Epigenesis, Genetic ,MECP2 ,Histones ,Behavioral Neuroscience ,Histone ,Memory ,Synaptic plasticity ,DNA methylation ,biology.protein ,Animals ,Epigenetics ,Neuroscience ,Gene - Abstract
The role of epigenetic mechanisms in control of gene expression during mammalian development is well established. Associations between specific DNA or histone modifications and numerous neurodevelopmental and neurodegenerative disorders implies significant consequences of epigenetic dysregulation in both the developing and mature brain, the latter of which is the general focus of this review. Accumulating evidence suggests that epigenetic changes are involved in normal cognitive processes in addition to neurological and psychiatric disorders. Recent investigations into the regulation of epigenetic modifications in the adult brain have revealed novel and surprisingly dynamic mechanisms for controlling learning and memory-related behaviors as well as long-term synaptic plasticity. DNA methylation and histone acetylation have also been implicated in the modulation of basal synaptic transmission and the balance between excitation and inhibition in various brain regions. Studies have begun to uncover some of the alterations in gene expression that appear to mediate many of these effects, but an understanding of the precise mechanisms involved is still lacking. Nevertheless, the fundamental importance of epigenetic processes in influencing neuronal activity is becoming increasingly evident.
- Published
- 2011
35. Behavioral epigenetics
- Author
-
J. David Sweatt, Barry E. Kosofsky, Michael J. Meaney, Ian Maze, Christopher W. Kuzawa, Edward Z. Tronick, Marcelo A. Wood, Johannes M. H. M. Reul, Ted Abel, Lisa M. Monteggia, David Skuse, Carmen J. Marsit, Barry M. Lester, and Eric J. Nestler
- Subjects
Behavioral epigenetics ,History and Philosophy of Science ,General Neuroscience ,Biology ,Neuroscience ,General Biochemistry, Genetics and Molecular Biology - Published
- 2011
36. Use-Dependent AMPA Receptor Block Reveals Segregation of Spontaneous and Evoked Glutamatergic Neurotransmission
- Author
-
Lisa M. Monteggia, Manjot Bal, Ege T. Kavalali, Yildirim Sara, and Megumi Adachi
- Subjects
Male ,Patch-Clamp Techniques ,Glutamic Acid ,Stimulation ,Tetrodotoxin ,AMPA receptor ,Biology ,Neurotransmission ,Hippocampus ,Article ,Mice ,Glutamatergic ,chemistry.chemical_compound ,Polyamines ,Animals ,Receptors, AMPA ,Anesthetics, Local ,Cells, Cultured ,Mice, Knockout ,Neurons ,musculoskeletal, neural, and ocular physiology ,General Neuroscience ,Glutamate receptor ,Excitatory Postsynaptic Potentials ,Lidocaine ,Philanthotoxin ,Valine ,Animals, Newborn ,nervous system ,chemistry ,Excitatory postsynaptic potential ,NMDA receptor ,Female ,Dizocilpine Maleate ,Excitatory Amino Acid Antagonists ,Neuroscience - Abstract
Earlier findings had suggested that spontaneous and evoked glutamate release activates non-overlapping populations of NMDA receptors. Here, we evaluated whether AMPA receptor populations activated by spontaneous and evoked release show a similar segregation. To track the receptors involved in spontaneous or evoked neurotransmission, we used a polyamine agent, philanthotoxin, that selectively blocks AMPA receptors lacking GluR2 subunits in a use-dependent manner. In hippocampal neurons obtained from GluR2-deficient mice, philanthotoxin application decreased AMPA-receptor-mediated spontaneous miniature EPSCs (AMPA-mEPSCs) down to 20% of their initial level within 5 min. In contrast, the same philanthotoxin application at rest decreased the subsequent AMPA-receptor-mediated evoked EPSCs (eEPSCs) only down to 80% of their initial value. A 10-min-long perfusion of philanthotoxin further decreased AMPA-eEPSC amplitudes to 60% of their initial magnitude, which remained substantially higher than the level of AMPA-mEPSC block achieved within 5 min. Finally, stimulation after removal of philanthotoxin resulted in reversal of AMPA-eEPSC block, verifying strict use dependence of philanthotoxin. These results support the notion that spontaneous and evoked neurotransmission activate distinct sets of AMPA receptors and bolster the hypothesis that synapses harbor separate microdomains of evoked and spontaneous signaling.
- Published
- 2011
37. Rett Syndrome and the Impact of MeCP2 Associated Transcriptional Mechanisms on Neurotransmission
- Author
-
Ege T. Kavalali and Lisa M. Monteggia
- Subjects
Regulation of gene expression ,Transcription, Genetic ,Methyl-CpG-Binding Protein 2 ,Rett syndrome ,Biology ,Neurotransmission ,medicine.disease ,Synaptic Transmission ,Article ,Chromatin remodeling ,MECP2 ,Synapses ,Synaptic plasticity ,DNA methylation ,Rett Syndrome ,medicine ,Humans ,Epigenetics ,Neuroscience ,Biological Psychiatry - Abstract
Subtle alterations in synaptic function contribute to the pathophysiology associated with several neuropsychiatric diseases. Modifications in synaptic vesicle trafficking can cause frequency-dependent changes in neurotransmission, alter information coding in neural circuits, and affect long-term plasticity. Rett syndrome, a neurodevelopmental disorder that arises from mutations in the methyl-CpG-binding protein-2 (MeCP2) gene, is a salient example for such a disease state in which synaptic transmission-in particular, spontaneous neurotransmission and short-term synaptic plasticity, have been altered. MeCP2 is widely believed to be a transcriptional repressor that silences methylated genes. Recent studies have identified synaptic deficits associated with the loss of MeCP2 in several brain regions, including the hippocampus. These findings suggest a synaptic basis for neurological symptoms associated with Rett syndrome and suggest an important role for transcriptional repression in the regulation of neurotransmission. These studies also highlight the importance of histone deacetylation and DNA methylation, two key epigenetic mechanisms in controlling synaptic function. These mechanisms are essential for chromatin remodeling in neurons as well as for repression of gene activation by MeCP2 and related methyl-binding proteins. Future work focusing on the regulation of DNA methylation and histone deacetylation by synaptic activity and how these epigenetic alterations affect neurotransmission will be critical to elucidate the mechanisms underlying Rett syndrome. In addition, this work will also help delineate a key pathway that regulates properties of neurotransmission in the central nervous system that may underlie additional neuropsychiatric disorders.
- Published
- 2009
38. MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function
- Author
-
Rhonda Bassel-Duby, John McAnally, Mi Sung Kim, James A. Richardson, Ana C. Barbosa, Ege T. Kavalali, Megumi Adachi, Eric N. Olson, Erika D. Nelson, Mert Ertunc, and Lisa M. Monteggia
- Subjects
Dendritic Spines ,Long-Term Potentiation ,Perforant Pathway ,Synaptogenesis ,Nonsynaptic plasticity ,Mice, Transgenic ,Biology ,Synaptic Transmission ,Synapse ,Mice ,Memory ,Animals ,Neuronal memory allocation ,Multidisciplinary ,MEF2 Transcription Factors ,Herpes Simplex Virus Protein Vmw65 ,Long-term potentiation ,Biological Sciences ,Myogenic Regulatory Factors ,Organ Specificity ,Dentate Gyrus ,Mutation ,Synapses ,Synaptic plasticity ,Excitatory postsynaptic potential ,Memory consolidation ,Neuroscience ,Gene Deletion ,Transcription Factors - Abstract
Learning and memory depend on the activity-dependent structural plasticity of synapses and changes in neuronal gene expression. We show that deletion of the MEF2C transcription factor in the CNS of mice impairs hippocampal-dependent learning and memory. Unexpectedly, these behavioral changes were accompanied by a marked increase in the number of excitatory synapses and potentiation of basal and evoked synaptic transmission. Conversely, neuronal expression of a superactivating form of MEF2C results in a reduction of excitatory postsynaptic sites without affecting learning and memory performance. We conclude that MEF2C limits excessive synapse formation during activity-dependent refinement of synaptic connectivity and thus facilitates hippocampal-dependent learning and memory.
- Published
- 2008
39. Hot Topics
- Author
-
Lisa M. Monteggia
- Subjects
Pharmacology ,Psychiatry and Mental health ,Autism spectrum disorder ,business.industry ,medicine ,Rett syndrome ,medicine.disease ,business ,Neuroscience - Published
- 2007
40. Postnatal loss of Mef2c results in dissociation of effects on synapse number and learning and memory
- Author
-
Megumi Adachi, Pei-Yi Lin, Heena Pranav, and Lisa M. Monteggia
- Subjects
0301 basic medicine ,Mef2 ,Autism Spectrum Disorder ,Dendritic Spines ,Hippocampus ,Motor Activity ,Article ,Synapse ,03 medical and health sciences ,Mice ,Memory ,Animals ,Learning ,Fear conditioning ,Biological Psychiatry ,Mice, Knockout ,Neuronal Plasticity ,Behavior, Animal ,MEF2 Transcription Factors ,Long-term potentiation ,musculoskeletal system ,Disease Models, Animal ,030104 developmental biology ,Synaptic plasticity ,Knockout mouse ,Memory consolidation ,Psychology ,Neuroscience - Abstract
Background Myocyte enhancer factor 2 (MEF2) transcription factors play critical roles in diverse cellular processes during central nervous system development. Studies attempting to address the role of MEF2 in brain have largely relied on overexpression of a constitutive MEF2 construct that impairs memory formation or knockdown of MEF2 function that increases spine numbers and enhances memory formation. Genetic deletion of individual MEF2 isoforms in brain during embryogenesis demonstrated that Mef2c loss negatively regulates spine numbers resulting in learning and memory deficits, possibly as a result of its essential role in development. Methods To investigate MEF2C function in brain further, we genetically deleted Mef2c during postnatal development in mice. We characterized these conditional Mef2c knockout mice in an array of behavioral paradigms and examined the impact of postnatal loss of Mef2c on long-term potentiation. Results We observed increased spine numbers in hippocampus of the conditional Mef2c knockout mice. However, the postnatal loss of Mef2c did not impact learning and memory, long-term potentiation, or social and repetitive behaviors. Conclusions Our findings demonstrate a critical role for MEF2C in the regulation of spine numbers with a dissociation of learning and memory, synaptic plasticity, and measures of autism-related behaviors in postnatal brain.
- Published
- 2015
41. A Neurotrophic Model for Stress-Related Mood Disorders
- Author
-
Lisa M. Monteggia and Ronald S. Duman
- Subjects
Adult ,Postmortem studies ,Models, Neurological ,Hippocampus ,Mice, Transgenic ,Mice ,Neurotrophic factors ,medicine ,Animals ,Humans ,Prefrontal cortex ,Biological Psychiatry ,Brain-derived neurotrophic factor ,biology ,Mood Disorders ,Brain-Derived Neurotrophic Factor ,Brain ,medicine.disease ,Antidepressive Agents ,Rats ,Disease Models, Animal ,nervous system ,Mood disorders ,biology.protein ,Antidepressant ,Psychology ,Neuroscience ,Stress, Psychological ,Neurotrophin - Abstract
There is a growing body of evidence demonstrating that stress decreases the expression of brain-derived neurotrophic factor (BDNF) in limbic structures that control mood and that antidepressant treatment reverses or blocks the effects of stress. Decreased levels of BDNF, as well as other neurotrophic factors, could contribute to the atrophy of certain limbic structures, including the hippocampus and prefrontal cortex that has been observed in depressed subjects. Conversely, the neurotrophic actions of antidepressants could reverse neuronal atrophy and cell loss and thereby contribute to the therapeutic actions of these treatments. This review provides a critical examination of the neurotrophic hypothesis of depression that has evolved from this work, including analysis of preclinical cellular (adult neurogenesis) and behavioral models of depression and antidepressant actions, as well as clinical neuroimaging and postmortem studies. Although there are some limitations, the results of these studies are consistent with the hypothesis that decreased expression of BDNF and possibly other growth factors contributes to depression and that upregulation of BDNF plays a role in the actions of antidepressant treatment.
- Published
- 2006
42. Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade
- Author
-
Elena Nosyreva, Lisa M. Monteggia, Ege T. Kavalali, and Anita E. Autry
- Subjects
antidepressant ,ketamine ,behavior ,Antagonist ,Hippocampus ,Long-term potentiation ,Pharmacology ,Hippocampal formation ,lcsh:RC321-571 ,Cellular and Molecular Neuroscience ,nervous system ,Synaptic plasticity ,medicine ,NMDA receptor ,Antidepressant ,Ketamine ,Original Research Article ,Psychology ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Neuroscience ,Molecular Biology ,development ,synaptic potentiation ,medicine.drug - Abstract
Ketamine is a NMDA receptor antagonist that produces rapid antidepressant responses in individuals with major depressive disorder. The antidepressant action of ketamine has been linked to blocking NMDA receptor activation at rest, which inhibits eukaryotic elongation factor2 kinase leading to desuppression of protein synthesis and synaptic potentiation in the CA1 region of the hippocampus. Here, we investigated ketamine mediated antidepressant response and the resulting synaptic potentiation in juvenile animals. We found that ketamine did not produce an antidepressant response in juvenile animals in the novelty suppressed feeding or the forced swim test. In addition ketamine application failed to trigger synaptic potentiation in hippocampal slices obtained from juvenile animals, unlike its action in slices from older animals (6-9 weeks old). The inability of ketamine to trigger an antidepressant response or subsequent synaptic plasticity processes suggests a developmental component to ketamine mediated antidepressant efficacy. We also show that the NMDAR antagonist AP5 triggers synaptic potentiation in mature hippocampus similar to the action of ketamine, demonstrating that global competitive blockade of NMDA receptors is sufficient to trigger this effect. These findings suggest that global blockade of NMDA receptors in developmentally mature hippocampal synapses are required for the antidepressant efficacy of ketamine.
- Published
- 2014
43. Regional, cellular, and subcellular localization of RGS10 in rodent brain
- Author
-
Jeff L. Waugh, Angela C. Lou, Amelia J. Eisch, E. Chris Muly, Lisa M. Monteggia, and Stephen J. Gold
- Subjects
Male ,Nervous system ,Hippocampus ,Biology ,Subgranular zone ,Rats, Sprague-Dawley ,Mice ,Microscopy, Electron, Transmission ,Species Specificity ,GTP-Binding Proteins ,medicine ,Animals ,Cell Nucleus ,Neurons ,Pyramidal Cells ,Stem Cells ,General Neuroscience ,Dentate gyrus ,Brain ,Gene Expression Regulation, Developmental ,Cell Differentiation ,Immunohistochemistry ,Rats ,Cell biology ,Mice, Inbred C57BL ,Parvalbumins ,medicine.anatomical_structure ,Dentate Gyrus ,Synapses ,Forebrain ,biology.protein ,Raphe Nuclei ,Microglia ,Pyramidal cell ,Neuroscience ,Nucleus ,RGS Proteins ,Parvalbumin ,Signal Transduction - Abstract
The regulator of G protein signaling type 10 (RGS10) modulates Gαi/o signaling by means of its GTPase accelerating activity and is abundantly expressed in brain and in immune tissues. To elucidate RGS10 function in the nervous system, we mapped RGS10 protein in rat and mouse brain using light microscopic (LM) and electron microscopic (EM) immunohistochemical techniques. The LM showed that RGS10-like immunoreactivity (LIR) labels all cellular subcompartments of neurons and microglia, including their nuclei. There were several differences between RGS10-LIR distributions in rat and mouse, the most striking of which were the far denser immunoreactivity in rat dentate gyrus and dorsal raphe. The EM analysis corroborated and extended our findings from LM. Thus, EM confirmed the presence of dense RGS10-LIR in the euchromatin compartment of nuclei. The EM analysis also resolved dense staining on terminals at symmetric synapses onto pyramidal cell somata. Dual immunofluorescence showed that forebrain interneurons densely labeled with RGS10-LIR partially colocalized with parvalbumin-LIR. Dual-labeling histochemistry in caudoputamen demonstrated that densely labeled striatal cells were biased to the indirect-projecting output pathway. Dual-labeling immunofluorescence also showed that densely labeled RGS10-LIR cells in the dentate gyrus subgranular zone were not proliferating but that newly born cells could differentiate to express RGS10-LIR. Taken together, these data support a role for RGS10 in diverse processes that include modulation of pre- and postsynaptic G-protein signaling. Moreover, enrichment of RGS10 in transcriptionally active regions of the nucleus suggests an unforeseen role of RGS10 in modulating gene expression. J. Comp. Neurol. 481:299–313, 2005. © 2004 Wiley-Liss, Inc.
- Published
- 2004
44. Neurobiology of Depression
- Author
-
Michel Barrot, Lisa M. Monteggia, Amelia J. Eisch, Ralph J. DiLeone, Stephen J. Gold, and Eric J. Nestler
- Subjects
biology ,Depression ,Neuroscience(all) ,General Neuroscience ,Hippocampus ,Nucleus accumbens ,CREB ,Amygdala ,Disease Models, Animal ,medicine.anatomical_structure ,Neurobiology ,Neurotrophic factors ,medicine ,biology.protein ,Animals ,Humans ,Antidepressant ,Aversive Stimulus ,Psychology ,Neuroscience ,Depression (differential diagnoses) - Abstract
Current treatments for depression are inadequate for many individuals, and progress in understanding the neurobiology of depression is slow. Several promising hypotheses of depression and antidepressant action have been formulated recently. These hypotheses are based largely on dysregulation of the hypothalamic-pituitary-adrenal axis and hippocampus and implicate corticotropin-releasing factor, glucocorticoids, brain-derived neurotrophic factor, and CREB. Recent work has looked beyond hippocampus to other brain areas that are also likely involved. For example, nucleus accumbens, amygdala, and certain hypothalamic nuclei are critical in regulating motivation, eating, sleeping, energy level, circadian rhythm, and responses to rewarding and aversive stimuli, which are all abnormal in depressed patients. A neurobiologic understanding of depression also requires identification of the genes that make individuals vulnerable or resistant to the syndrome. These advances will fundamentally improve the treatment and prevention of depression.
- Published
- 2002
45. A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory
- Author
-
Melissa Mahgoub and Lisa M. Monteggia
- Subjects
Epigenetics in learning and memory ,Cognitive Neuroscience ,Review ,Chromatin remodeling ,Histone Deacetylases ,Epigenesis, Genetic ,Cellular and Molecular Neuroscience ,Mice ,Memory ,Animals ,Humans ,Learning ,Transcription factor ,Histone Acetyltransferases ,Genetics ,Neurons ,Histone deacetylase 5 ,Neuronal Plasticity ,biology ,Brain ,Neurodegenerative Diseases ,Chromatin Assembly and Disassembly ,Chromatin ,Histone Deacetylase Inhibitors ,Neuropsychology and Physiological Psychology ,Histone ,Acetylation ,biology.protein ,Neuroscience - Abstract
Histone deacetylases (HDACs) are a family of chromatin remodeling enzymes that restrict access of transcription factors to the DNA, thereby repressing gene expression. In contrast, histone acetyltransferases (HATs) relax the chromatin structure allowing for an active chromatin state and promoting gene transcription. Accumulating data have demonstrated a crucial function for histone acetylation and histone deacetylation in regulating the cellular and behavioral mechanisms underlying synaptic plasticity and learning and memory. In trying to delineate the roles of individual HDACs, genetic tools have been used to manipulate HDAC expression in rodents, uncovering distinct contributions of individual HDACs in regulating the processes of memory formation. Moreover, recent findings have suggested an important role for HDAC inhibitors in enhancing learning and memory processes as well as ameliorating symptoms related to neurodegenerative diseases. In this review, we focus on the role of HDACs in learning and memory, as well as significant data emerging from the field in support of HDAC inhibitors as potential therapeutic targets for the treatment of cognitive disorders.
- Published
- 2014
46. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
- Author
-
Carlos A. Zarate and Lisa M. Monteggia
- Subjects
Clinical Trials as Topic ,Depression ,General Neuroscience ,Glutamate receptor ,Neurotransmission ,Receptors, N-Methyl-D-Aspartate ,Antidepressive Agents ,Article ,Blockade ,Clinical Practice ,Glutamatergic ,medicine ,NMDA receptor ,Antidepressant ,Humans ,Ketamine ,Psychology ,Neuroscience ,medicine.drug - Abstract
In the past decade the emergence of glutamate N-methyl-d-aspartate (NMDA) receptor blockers such as ketamine as fast-acting antidepressants fostered a major conceptual advance by demonstrating the possibility of a rapid antidepressant response. This discovery brings unique mechanistic insight into antidepressant action, as there is a substantial amount of basic knowledge on glutamatergic neurotransmission and how blockade of NMDA receptors may elicit plasticity. The combination of this basic knowledge base and the growing clinical findings will facilitate the development of novel fast acting antidepressants.
- Published
- 2014
47. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses
- Author
-
Lisa M. Monteggia, Ege T. Kavalali, and Erinn S. Gideons
- Subjects
Male ,Patch-Clamp Techniques ,Time Factors ,Blotting, Western ,Neurotransmission ,Pharmacology ,Motor Activity ,Hippocampus ,Receptors, N-Methyl-D-Aspartate ,Mice ,Peptide Elongation Factor 2 ,Memantine ,medicine ,Animals ,Humans ,Ketamine ,Magnesium ,Phosphorylation ,Cells, Cultured ,Brain-derived neurotrophic factor ,Neurons ,Multidisciplinary ,Brain-Derived Neurotrophic Factor ,Antagonist ,Excitatory Postsynaptic Potentials ,Psychotomimetic ,Biological Sciences ,Antidepressive Agents ,Mice, Inbred C57BL ,nervous system ,Animals, Newborn ,NMDA receptor ,Antidepressant ,Psychology ,Neuroscience ,Excitatory Amino Acid Antagonists ,medicine.drug - Abstract
Ketamine is an NMDA receptor (NMDAR) antagonist that elicits rapid antidepressant responses in patients with treatment-resistant depression. However, ketamine can also produce psychotomimetic effects that limit its utility as an antidepressant, raising the question of whether the clinically tolerated NMDAR antagonist memantine possesses antidepressant properties. Despite its similar potency to ketamine as an NMDAR antagonist, clinical data suggest that memantine does not exert rapid antidepressant actions for reasons that are poorly understood. In this study, we recapitulate the ketamine and memantine clinical findings in mice, showing that ketamine, but not memantine, has antidepressant-like effects in behavioral models. Using electrophysiology in cultured hippocampal neurons, we show that ketamine and memantine effectively block NMDAR-mediated miniature excitatory postsynaptic currents in the absence of Mg(2+). However, in physiological levels of extracellular Mg(2+), we identified key functional differences between ketamine and memantine in their ability to block NMDAR function at rest. This differential effect of ketamine and memantine extends to intracellular signaling coupled to NMDAR at rest, in that memantine does not inhibit the phosphorylation of eukaryotic elongation factor 2 or augment subsequent expression of BDNF, which are critical determinants of ketamine-mediated antidepressant efficacy. These results demonstrate significant differences between the efficacies of ketamine and memantine on NMDAR-mediated neurotransmission that have impacts on downstream intracellular signaling, which we hypothesize is the trigger for rapid antidepressant responses. These data provide a novel framework on the necessary functional requirements of NMDAR-mediated neurotransmission as a critical determinant necessary to elicit rapid antidepressant responses.
- Published
- 2014
48. Withdrawal from repeated amphetamine administration reduces NMDAR1 expression in the rat substantia nigra, nucleus accumbens and medial prefrontal cortex
- Author
-
Lisa M. Monteggia, Wenxiao Lu, and Marina E. Wolf
- Subjects
medicine.medical_specialty ,Chemistry ,General Neuroscience ,Substantia nigra ,Nucleus accumbens ,Ventral tegmental area ,Midbrain ,medicine.anatomical_structure ,Endocrinology ,nervous system ,Dopamine ,Internal medicine ,medicine ,NMDA receptor ,Amphetamine ,Prefrontal cortex ,Neuroscience ,medicine.drug - Abstract
Glutamate plays a critical role in neuroadaptations induced by drugs of abuse. This study determined whether expression of the NMDAR1 subunit of the NMDA receptor is altered by repeated amphetamine administration. We quantified NMDAR1 mRNA (using in situ hybridization with 35S-labelled oligonucleotide probes) and immunolabelling (using immunocytochemistry with 35S-labelled secondary antibodies) in rat ventral midbrain, nucleus accumbens and prefrontal cortex after 3 or 14 days of withdrawal from five daily injections of saline or amphetamine sulphate (5 mg/kg/day). No changes in NMDAR1 expression were observed after 3 days of withdrawal, whereas significant decreases were observed in all regions after 14 days. NMDAR1 mRNA levels in midbrain were too low for reliable quantification, but immunolabelling was decreased significantly in intermediate and caudal portions of the substantia nigra. This may indicate a reduction in excitatory drive to substantia nigra dopaminergic neurons. In the nucleus accumbens, there were significant decreases in NMDAR1 mRNA levels (74.8 +/- 7. 7% of control, P < 0.05) and immunolabelling (76.7 +/- 4.4%, P < 0. 05). This may account for previously-reported decreases in the electrophysiological responsiveness of nucleus accumbens neurons to NMDA after chronic amphetamine treatment, and contribute to dysregulation of goal-directed behaviour. In prefrontal cortex, there was a significant decrease in NMDAR1 mRNA levels (76.1 +/- 7. 1%, P < 0.05) and a trend towards decreased immunolabelling (89.5 +/- 7.0%). This may indicate decreased neuronal excitability within prefrontal cortex. A resultant decrease in activity of excitatory prefrontal cortical projections to nucleus accumbens or midbrain could synergize with local decreases in NMDAR1 to further reduce neuronal excitability in these latter regions.
- Published
- 1999
49. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein
- Author
-
Wilhelm Bloch, Jon Lindstrom, Andrea Wevers, Hannsjörg Schröder, Howard M. Eisenberg, Alfred Maelicke, R. A. I. de Vos, Edna F. R. Pereira, Ulrich Schütz, E.N.H. Jansen Steur, Edson X. Albuquerque, Lisa M. Monteggia, Ezio Giacobini, and Sonja Nowacki
- Subjects
Male ,Amyloid ,Tau protein ,Plaque, Amyloid ,tau Proteins ,Receptors, Nicotinic ,complex mixtures ,Alzheimer Disease ,Cortex (anatomy) ,mental disorders ,medicine ,Humans ,Protein Isoforms ,RNA, Messenger ,Phosphorylation ,Aged ,Aged, 80 and over ,Cerebral Cortex ,Neurons ,Amyloid beta-Peptides ,biology ,General Neuroscience ,Human brain ,Frontal Lobe ,Nicotinic acetylcholine receptor ,medicine.anatomical_structure ,Nicotinic agonist ,nervous system ,Cerebral cortex ,biology.protein ,Cholinergic ,Female ,sense organs ,Neuroscience - Abstract
Impairment of cholinergic transmission and decreased numbers of nicotinic binding sites are well-known features accompanying the cognitive dysfunction seen in Alzheimer's disease (AD). In order to elucidate the underlying cause of this cholinoceptive dysfunction, the expression of two pharmacologically different nicotinic acetylcholine receptor (nAChR) subunits (alpha4, alpha7) was studied in the cerebral cortex of Alzheimer patients as compared to controls. Patch-clamp recordings of 14 dissociated neurons of control cortices showed responses suggesting the existence of alpha4- and alpha7-containing functional nAChRs in the human cortex. In cortices of Alzheimer patients and controls, the pattern of distribution and the number of alpha4 and alpha7 mRNA-expressing neurons were similar, whereas at the protein level a decrease in the density of alpha4- and alpha7-expressing neurons of approximately 30% was observed in Alzheimer patients. The histotopographical correlation of nAChR expression with accompanying pathological changes, e.g. accumulation of hyperphosphorylated-tau (HP-tau) protein and beta-amyloid showed that neurons in the vicinity of beta-amyloid plaques bore both nAChR transcripts. Neurons heavily labelled for HP-tau, however, expressed little or no alpha4 and alpha7 mRNA. These results point to an impaired synthesis of nAChRs on the protein level as a possible cause of the cholinoceptive deficit in AD. Further investigations need to elucidate whether interactions of HP-tau with nAChR mRNA, or alterations in the quality of alpha4 and alpha7 transcripts give rise to decreased protein expression at the level of individual neurons.
- Published
- 1999
50. Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor
- Author
-
Takanori Hashimoto, Nutan Kolluri, Justin J. Hill, Allan R. Sampson, David A. Lewis, Qiang Wu, and Lisa M. Monteggia
- Subjects
Mice, Knockout ,Brain-derived neurotrophic factor ,Psychosis ,Messenger RNA ,Dendritic spine ,Brain-Derived Neurotrophic Factor ,Pyramidal Cells ,Embryogenesis ,Prefrontal Cortex ,Dendrites ,Biology ,medicine.disease ,Mice ,nervous system ,Neurotrophic factors ,medicine ,Animals ,RNA, Messenger ,Prefrontal cortex ,Neuroscience ,Biological Psychiatry ,Gene knockout - Abstract
Background The messenger ribonucleic acid (mRNA) for brain-derived neurotrophic factor (BDNF), a regulator of pyramidal neuron dendritic spine density during development, is decreased in the prefrontal cortex of subjects with schizophrenia, and the level of BDNF mRNA expression is positively correlated with dendritic spine density in the same subjects. Methods To determine whether reduced BDNF mRNA expression might account for decreased spine density in schizophrenia, a knockout of the BDNF gene was induced in mice during embryogenesis or at 12 weeks of age. Quantitative assessments were made of the dendritic arbor of Golgi-impregnated pyramidal neurons in the prelimbic and anterior cingulate cortices in adulthood. Results Despite an 80% reduction in BDNF mRNA levels in both knockouts, neither spine density nor other dendritic or somal measures were decreased compared with wild-type animals. Conclusions A reduction in BDNF expression alone does not seem to be sufficient to alter pyramidal neuron morphology in mice. This finding suggests that other molecular abnormalities are also required to produce the pyramidal neuron dendritic spine abnormalities observed in schizophrenia.
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.